Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.

Leukemia - 1 Jan 2013

Ren M, Qin H, Ren R, Cowell J K

Abstract excerpt

Myeloid and lymphoid malignancies associated with fibroblast growth factor receptor-1 (FGFR1) abnormalities are characterized by constitutively activated FGFR1 kinase and rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. Molecular targeted therapies have not been widely used for stem cell leukemia/lymphoma (SCLL). Ponatinib (AP24534), which potently inhibits native and mutant BCR-ABL,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to Imidazoles
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Promyelocytic, Acute

Share to Mice, Inbred NOD

Share to Precursor Cells, B-Lymphoid

Share to Pyridazines

Share to Receptor, Fibroblast Growth Factor, Type 1

Source

Open in PubMed Open full text

Identifiers

PMID: 22781593
DOI: 10.1038/leu.2012.188
PMCID: PMC3629706

Genes

FGFR1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.PMID 22781593Read ↗

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.Semantic proximity Read ↗

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeSemantic proximity Read ↗

Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.Semantic proximity Read ↗

Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1Semantic proximity Read ↗

Targeting FGFR1 to suppress leukemogenesis in syndromic and <i>de novo</i> AML in murine modelsSemantic proximity Read ↗

Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.Semantic proximity Read ↗

Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinasesSemantic proximity Read ↗

Src Activation Plays an Important Key Role in Lymphomagenesis Induced by FGFR1 Fusion KinasesSemantic proximity Read ↗

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).Semantic proximity Read ↗

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.Semantic proximity Read ↗

Ponatinib in the therapy of chronic myeloid leukemia.Semantic proximity Read ↗

Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.